Cystic Fibrosis Transmembrane Conductance Regulator Facilitates ATP Release by Stimulating a Separate ATP Release Channel for Autocrine Control of Cell Volume Regulation*

Gavin M. BraunsteinDagger , Richard M. Roman§, John P. Clancy||, Brian A. KudlowDagger , Amanda L. Taylor**, Vadim Gh. ShylonskyDagger , Biljana JovovDagger , Krisztina Peter**, Tamas JillingDagger Dagger , Iskander I. IsmailovDagger , Dale J. BenosDagger , Lisa M. SchwiebertDagger **, J. Greg Fitz§, and Erik M. SchwiebertDagger **§§

From the Dagger  Department of Physiology and Biophysics, ** Department of Cell Biology,  Gregory Fleming James Cystic Fibrosis Research Center, || Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama 35294-0005, the § Division of Hepatology, University of Colorado Health Sciences Center, Denver, Colorado, 80262, and the Dagger Dagger  Department of Pediatrics, The Evanston Hospital, Evanston, Illinois 60201

Received for publication, July 5, 2000, and in revised form, November 9, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

These studies provide evidence that cystic fibrosis transmembrane conductance regulator (CFTR) potentiates and accelerates regulatory volume decrease (RVD) following hypotonic challenge by an autocrine mechanism involving ATP release and signaling. In wild-type CFTR-expressing cells, CFTR augments constitutive ATP release and enhances ATP release stimulated by hypotonic challenge. CFTR itself does not appear to conduct ATP. Instead, ATP is released by a separate channel, whose activity is potentiated by CFTR. Blockade of ATP release by ion channel blocking drugs, gadolinium chloride (Gd3+) and 4,4'-diisothiocyanatostilbene-2,2'disulfonic acid (DIDS), attenuated the effects of CFTR on acceleration and potentiation of RVD. These results support a key role for extracellular ATP and autocrine and paracrine purinergic signaling in the regulation of membrane ion permeability and suggest that CFTR potentiates ATP release by stimulating a separate ATP channel to strengthen autocrine control of cell volume regulation.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

ATP and its metabolites function as potent autocrine and paracrine agonists that act within tissues to control cell function through activation of P2 purinergic receptors (1-3) expressed by all cells and tissues. Purinergic agonists are essential for many specialized physiological functions (1-10). In cystic fibrosis (CF),1 ATP and a related triphosphate nucleotide, UTP, stimulate epithelial chloride (Cl-) channels alternative to CFTR via purinergic receptors (11-16). Supraphysiological concentrations of ATP also stimulate CFTR (17). Metabolites of ATP can also act as Cl- secretagogues (15, 16, 18). Despite the diverse roles of purinergic signaling, the cellular mechanisms that govern ATP release are not fully defined. CFTR and related ATP-binding cassette (ABC) transporters such as mdr-1 or P-glycoprotein have been implicated as facilitators of ATP release in some cell models (14, 19-24), while other laboratories have failed to show evidence of CFTR-facilitated ATP conduction or release (25-30).

Release of ATP via a conductive pathway has been implicated as an essential autocrine regulator of cell volume in rat hepatoma cells (5). Moreover, ABC transporters have been shown to modulate volume-sensitive Cl- channels and cell volume (31-34). As such, we tested the hypotheses that CFTR facilitates ATP release under constitutive and hypotonic conditions for autocrine control of cell volume regulation. These hypotheses were also based on the fact that airway surface liquid on CF epithelia is hypertonic with respect to NaCl (35) and/or reduced in volume (36) or both (37, 38) when compared with non-CF epithelia. These airway surface liquid composition abnormalities may reflect an inability of CF epithelial cells to sense changes in external mucosal environment and/or an inability of CF cells to regulate their own cell volume.

To this end, complimentary observations using a variety of techniques suggest that expression of CFTR enhances ATP release and modulates the dynamic relationship between cell volume, purinergic signaling, and membrane ion permeability. Given the cellular challenges related to changes in solute transport and maintenance of airway surface liquid, defective cell volume regulation in CF epithelia may underlie the pathogenesis of CF in the lung and airways.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- The 16HBE14o- non-CF human bronchial epithelial cell line, the 9HTEo- non-CF human tracheal epithelial cell line, and the CFBE41o- CF human bronchial epithelial cell line (homozygous for the Delta F508-CFTR mutation) were grown as described previously (39-42). COS-7 cells were grown in similar medium. Parental CFPAC-1 CF human pancreatic epithelial cells and CFPAC-1 cells complemented stably with the wild-type CFTR gene (CFPAC-PLJ-WT clone 20) were grown in similar medium without and with G418 (1 mg/ml; Cellgro/Mediatech) (43). 3T3-CFTR fibroblasts expressing wild-type CFTR (3T3-WT-H7), expressing Delta F508-CFTR (3T3-Delta F508), or mock-transfected (3T3-Mock) were a generous gift from Michael Welsh (University of Iowa, Iowa City, Iowa, Howard Hughes Medical Institute) (44) and were grown in a similar medium except that a Dulbecco's minimal essential medium with high glucose (Life Technologies, Inc.) was used as the basal medium. CFT-1 cells were grown in LHC-8 medium (Biofluids; Rockville, MD) without serum. For consistency, all CFTR cell models were grown on similar substrates and in similar media.

Transient Transfection of COS-7 Cells with LipofectAMINE PLUS-- COS-7 cells were seeded to 33% confluence 1 day prior to transfection with LipofectAMINE PLUSTM reagent (Life Technologies, Inc.) (45-47). To control for transfection efficiency and to correlate relative CFTR protein expression from culture to culture, triple transfections were performed with different CFTR mammalian expression vectors bearing wild-type or mutant CFTR together with green fluorescence protein- and luc-bearing mammalian expression vectors. Green fluorescence protein expression was assessed in each culture as was luc protein expression to standardize ATP release assays in the transient transfection cultures.

Transient Infection of COS-7 Cells with Vaccinia Virus-- These methods have been published previously (48).

Bioluminescent Detection of Released ATP from Heterologous Cell Cultures and Epithelial Monolayers-- The specifics of this assay have been published previously (42). Fibroblasts were grown to or near confluence on collagen-coated dishes. Epithelial cells were seeded at high density (at least 105 cells per filter) onto collagen-coated permeable supports (Millicell).

Analysis of Chloride and ATP Channel Activity in a Panel of CFTR Protein Preparations in Planar Lipid Bilayers-- These methods have been published previously (49, 50).

Coulter Counter Channelyzer Analysis of Cell Volume-- Mean cell volume was measured in cell suspensions by electronic cell sizing (Coulter Multisizer II, AccuComp software version 1.19, Hialeah, FL) using an 100-µm aperture. Cells in subconfluent culture were harvested with minimal trypsin (0.05%), suspended in cell culture medium, centrifuged for 1 min at 1,000 × g, resuspended in 3 ml of isotonic buffer, and incubated with gentle agitation for 30-45 min. Aliquots (~500 µl) of cell suspension were added to 20 ml of isotonic or hypotonic (40% less NaCl) buffer. Measurements of 20,000 cells on average at specified time points after exposure to isotonic or hypotonic buffer were compared with basal values in isotonic buffer (time 0). Changes in values were expressed as relative volume normalized to the basal period (5).

SPQ Halide Permeability Assay-- SPQ (Molecular Probes) was solubilized in cell culture medium at a concentration of 2 mg/ml and was loaded into cell by an overnight incubation. The protocol was 2 min in NaI Ringer followed by 2-3 min in NaNO3 Ringer and then several minutes in NaNO3 Ringer containing forskolin or diluted by 25% with distilled water. Responses were reversed fully in NaI Ringer. Specific concerning the SPQ assay and system have been published previously (48).

Immunoprecipitation of CFTR Protein-- Freshly grown epithelial cells or fibroblasts (a single 35-mm dish or 12-mm diameter filter confluent and/or tight to fluid) were lysed for 30 min at 4 °C in a buffer containing 20 mM HEPES, 150 mM NaCl, 1 mM EDTA, and 1% Nonidet P-40 (pH 7.4) supplemented with 1 mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mg/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride. These samples were immunoprecipitated with anti-CFTR antibody as described previously (47).

Cellular Cyclic AMP Bioassay-- These methods have been published previously (48).

Data Analysis and Statistics-- Data values were compiled into Microsoft Excel spreadsheets in which the mean ± S.E. was calculated for each time point in each set of experimental time courses. Data were then plotted in SigmaPlot for Windows using the same arbitrary light unit values. Statistics were performed using SigmaStat for Windows; paired Student's t test or unpaired ANOVA with a Bonferroni ad-hoc test were performed as appropriate. A p value of <0.05 was considered significant.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Wild-type (WT) CFTR Potentiates and Accelerates Regulatory Volume Decrease (RVD)-- To evaluate whether CFTR expression plays a role in cell volume regulation, cell volume recovery from swelling induced by hypotonic challenge (e.g. RVD) was assessed in cells stably expressing wild-type CFTR (WT-CFTR) versus Delta F508-CFTR (Fig. 1A). In all cells, hypotonic exposure caused an initial increase in cell volume to a similar degree that peaked at 2 min following challenge (Fig. 1A). However, expression of WT-CFTR accelerated the rate of RVD 2-fold when compared with fibroblasts devoid of CFTR (not shown) or expressing the Delta F508-CFTR mutation (Fig. 1, A and B). When expressed as percent recovery from peak swelling, expression of WT-CFTR increased the rate of volume recovery 2-fold (Fig. 1B). Taken together, these results show that wild-type CFTR accelerates and potentiates cell volume regulation.



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1.   Wild-type, but not Delta F508-CFTR, accelerates and potentiates RVD dynamics: dependence of RVD on CFTR, ATP release, and extracellular ATP signaling. A, raw cell volume data illustrating the difference in RVD dynamics between wild-type CFTR- and Delta F508-CFTR-expressing fibroblasts (n = 3 for each cell type for this representative data set; n = 6 overall). Using a confidence interval of 0.99 for a linear regression, the slope of the line fit to the cell volume values measured from the peak of hypotonicity-induced cell swelling to the end of the RVD time course was measured to estimate the rate (* reflects p < 0.05 significance in slope of RVD dynamics by ANOVA). The slope of the wild-type CFTR RVD time course was -4.77 × 10-3, while the Delta F508-CFTR RVD slope was -2.93 × 10-3. B, percent RVD from the peak of swelling (2 min) to the 30-min time point following RVD is plotted (* reflects p < 0.05 significance by ANOVA). C, apyrase (1 unit/ml) blocks RVD in wild-type CFTR-expressing fibroblasts; this effect is rescued fully by ATPgamma S (25 µM) (n = 3 for each fibroblast clone). Note different expanded scale on the graph in C versus A.

WT-CFTR-facilitated RVD Depends upon Extracellular ATP Signaling-- To assess whether the effects of CFTR expression on cell volume regulation are related to release of ATP, the effects of the ATP scavenger apyrase were determined. In fibroblasts expressing WT-CFTR, depletion of extracellular ATP by apyrase blocked RVD completely (Fig. 1C). Addition of ATPgamma S, a poorly hydrolyzable ATP analog resistant to apyrase, reversed this inhibition (Fig. 1C). These results suggest that extracellular ATP is required for RVD and for maintenance of cell volume.

WT-CFTR Potentiates ATP Release under Basal Conditions-- To determine whether these effects of CFTR on volume regulation are related to ATP release, additional studies were performed using a luciferin-luciferase assay to quantify ATP release into the medium (Fig. 2A). Under basal conditions, WT-CFTR-expressing fibroblasts release 3-fold greater ATP than mock-transfected fibroblasts and 2-fold greater ATP than Delta F508-CFTR-expressing fibroblasts (Fig. 2A). Interestingly, ATP release was always detectable (above background), even in the absence of CFTR or in the presence of Delta F508-CFTR, suggesting that the ATP release mechanism is an entity separate from the ABC transporter itself.



View larger version (35K):
[in this window]
[in a new window]
 
Fig. 2.   ABC transporters augment ATP release under basal or isotonic conditions. A, luminescence values in arbitrary light units (ALU) from mock or WT-CFTR- or Delta F508-CFTR-expressing fibroblasts. Data from COS-7 cells lacking or transiently expressing WT-CFTR or Delta F508-CFTR is provided in the text. Experimental number (n) is shown in each bar in A. Data are expressed as mean ± S.E. (* reflects p < 0.01 value for ATP release significantly greater than control, ** reflects p < 0.05 value for ATP release significantly greater than control, ANOVA and a Bonferroni ad-hoc test). B, immunoprecipitations of WT and Delta F508-CFTR protein in fibroblasts lacking or stably expressing wild-type CFTR or Delta F508-CFTR and in COS-7 cells lacking or transiently expressing wild-type or mutant CFTR proteins (representative of three independent experiments in each heterologous system).

Additional studies were performed to assess the effects of transient transfection of CFTR on ATP release using COS-7 cells. Mock-transfected cells had no detectable CFTR. WT-CFTR-transfected cells expressed both partially (band B) and fully glycosylated (band C) forms of CFTR, while Delta F508-CFTR-transfected cells had only the partially glycosylated band B form of CFTR (47, 51). To more carefully monitor the amount of transduction of a given heterologous cell with CFTR, COS-7 cells were transfected transiently with two different WT-CFTR constructs or a Delta F508-CFTR constructs (Fig. 2B). Similar results were also found in the fibroblast clones stably expressing WT-CFTR and Delta F508-CFTR (Fig. 2B). As in the fibroblast clones studied above, wild-type CFTR potentiated ATP release 2.9 ± 0.5-fold when cultures were studied 48 h post-transfection, while Delta F508-CFTR failed to potentiate ATP release (1.2 ± 0.5-fold; mock-transfected and parental data normalized to 1-fold; n = 6-9). Taken together, these data show that wild-type CFTR potentiates ATP release from cells under basal conditions.

WT-CFTR Potentiates and Sensitizes Hypotonicity-induced ATP Release-- Because WT-CFTR potentiates RVD and ATP release, we tested the hypothesis that CFTR may also potentiate ATP release triggered by an increase in cell volume after a hypotonic challenge. Hypotonic challenge to increase cell volume triggered an immediate and robust increase in ATP release from non-CF epithelia expressing WT-CFTR (Fig. 3A). As little as 4% dilution triggered a change in luminescence of Delta +10.9 ALU from non-CF epithelia (Fig. 3A). In sharp contrast, 33% dilution was required to stimulate any ATP release (only a Delta +0.7 ALU) from CFBE41o- monolayers. These results were confirmed by another model of CF. In CFPAC-1 monolayers lacking CFTR, a large dilution of 24% was again required to elicit a small change (only a Delta +1.6 ALU) in ATP release (Fig. 3A). When CFPAC-1 monolayers are stably complemented with WT-CFTR, as little as 4% dilution is enough to trigger ATP release (Delta +6.8 ALU) (Fig. 3A). When challenged with more robust dilutions of the medium osmolality, 51% hypotonicity triggered a robust ATP release in WT-CFTR-expressing non-CF epithelia (Delta +48.7 ALU) and in WT-CFTR-complemented CFPAC-1 monolayers (Delta +33.0 ALU) (Fig. 3A). In contrast, 51% dilution with distilled water only stimulated small increases in luminescence in CFBE41o- monolayers (Delta +3.0 ALU) and in CFPAC-1 monolayers (Delta +3.9 ALU)) (Fig. 3A). Taken together, these results show that WT-CFTR potentiates ATP release into the apical medium and heightens the sensitivity of the apical membrane of the epithelium to hypotonic challenge and subsequent increases in cell volume.



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   CFTR augments the sensitivity to hypotonic challenge and the magnitude of hypotonicity-induced ATP release in epithelial cell monolayers across the apical membrane. A, hypotonicity-induced ATP release into the apical medium (graphed as luminescence in ALU) for non-CF airway epithelial (16HBE14o-) monolayers, CF airway epithelial (CFBE41o-) monolayers, CF pancreatic epithelial (CFPAC-1) monolayers, and WT-CFTR-complemented CFPAC-1 epithelial monolayers. Apical-directed ATP release triggered by hypotonicity was significantly greater in non-CF and WT-CFTR-complemented monolayers versus CF monolayers expressing the Delta F508-CFTR mutation (ANOVA, p < 0.05 or lower at all dilutions; n = 6-8). Data shown for all cells is graphed on the same scale to show the lack of responsiveness of the CF cell models. B, immunoprecipitation of WT-CFTR band C protein from non-CF, but not the CF airway epithelial cell monolayers (representative of three independent experiments).

To better define CFTR protein expression in these non-CF and CF airway epithelial cell lines, immunoprecipitation of CFTR protein was performed in parallel. Expression of the mature band C form of CFTR protein was demonstrated in the non-CF 16HBE14o- cell line with a trace amount of the band B form (Fig. 3B). In sharp contrast, the CF human airway epithelial cell line (CFBE41o-) lacked any detectable CFTR protein (Fig. 3B). Characterization of the parental CFPAC-1 cells and the stably complemented CFPAC-1 clone have been published previously (43). Thus, these dynamic changes in ATP release correlate with expression of CFTR protein.

WT-CFTR Potentiates Volume-sensitive ATP Release: Further Potentiation by Cyclic AMP in WT-CFTR-Expressing Fibroblasts-- Because the cyclic AMP-dependent protein kinase signaling cascade stimulates CFTR chloride channel (51) and because cyclic AMP stimulates ATP release in WT-CFTR-expressing cells (14, 23), we tested the hypothesis that protein kinase A activity modulates hypotonicity-induced ATP release. A typical time course of the response to forskolin (2 µM) and to 33% dilution of the medium osmolality is shown in Fig. 4A. Forskolin stimulated ATP release transiently and only in fibroblasts expressing WT-CFTR (Fig. 4A). Hypotonicity stimulated ATP release in all three fibroblast clones, but most robustly in WT-CFTR-expressing fibroblasts (Fig. 4B). More intriguingly, pretreatment with forskolin potentiated volume-sensitive ATP release, but, again, only in WT-CFTR-expressing fibroblasts (Fig. 4B), where values increased 3-fold above those in the absence of cyclic AMP (Fig. 4B). No such enhancement was observed in mock or Delta F508-CFTR-expressing fibroblasts (Fig. 4B). These results suggest that cyclic AMP and hypotonicity function in a synergistic manner to stimulate ATP release, but only in cells expressing WT-CFTR.



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 4.   CFTR augments hypotonicity-induced ATP release in two different heterologous cell culture systems: hypotonicity-induced ATP release is potentiated by cyclic AMP, but only in wild-type CFTR-expressing cells. A, typical time course of forskolin (2 µM)- and hypotonicity-induced ATP release in wild-type CFTR-expressing fibroblasts versus mock and Delta F508-expressing controls. Forskolin potentiated ATP release (p < 0.01 in the first minute following stimulation by paired Student's t test, n = 6), but only in wild-type CFTR-expressing cells. B, summary of data shown in A. Hypotonicity stimulated ATP release that was significantly elevated throughout stimulation in all clones; forskolin potentiated that release, but only in wild-type CFTR-expressing cells (ANOVA, p < 0.01 in the first minute following stimulation, n = 6).

CFTR Is Closely Associated with an ATP Release Channel That Appears Separate from the CFTR Channel Protein-- To further define whether CFTR conducts ATP or whether CFTR is closely associated with a separate ATP release channel, protein preparations containing or lacking WT-CFTR were analyzed for both Cl- and ATP- single channel conductance in planar lipid bilayers. The protein preparation used in these bilayer studies represents an epithelial cell protein extract from membrane vesicles derived from epithelial cells (49, 50). Consistent with the studies of Kopito and co-workers and of Bear and colleagues (28, 30), CFTR immunoprecipitated and highly purified from this epithelial vesicle protein and fused with planar lipid bilayers formed channels that conducted Cl- in 18 out of 18 preparations (Cl- conductance = 11 ± 2 picosiemens) in which channels were observed. DPC (200 µM) blocked CFTR Cl- channel activity, while DIDS or gadolinium chloride (200 µM each) had no effect on CFTR Cl- channel activity (data not shown). Conversely, an ATP conductance was observed in only 1 out of 18 preparations (ATP conductance = 22 picosiemens). We hypothesized that this one example of ATP channel activity may represent the fusion and activity of a contaminating protein that conducts ATP. In support of this latter hypothesis, less pure vesicle protein preparations containing CFTR and other proteins were also examined (Fig. 5A). In this preparation, CFTR Cl- channels, outwardly rectifying Cl- channels (ORCCs), and ATP channels were observed frequently and in similar incidence (see example in Fig. 5A). In these recordings, ATP channel activity was recorded first in symmetrical 100 mM NaATP, so as not to have possible contamination by Cl- channel activity or by trace amounts of Cl- in the recording chamber. Subsequently, ORCC and CFTR Cl- channel activity were observed when ATP-containing solutions were replaced with Cl--containing solutions (Fig. 5A). Addition of DIDS (300 µM) inhibited ORCCs, while DPC blocked residual CFTR Cl- channel activity (Fig. 5A). These results show that two different Cl- conductances and an ATP conductance are present in this bovine tracheal epithelial vesicle protein material that contains CFTR. However, because highly purified CFTR does not appear to reliably conduct ATP, this ATP conductance is likely not conferred by CFTR, but may be conferred by another anion channel protein.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Chloride and ATP conductances in less purified CFTR-containing and CFTR-immunodepleted protein preparations: highly purified CFTR cannot conduct ATP. A, lipid bilayer recording of less purified bovine tracheal epithelial vesicle protein preparation in which an ATP channel was observed initially in symmetrical Na2ATP solutions, followed by recording of both ORCC and then CFTR Cl- channel activity (after DIDS was applied to block the ORCC) in 100 mM CsCl (n = 5). B, ATP channel activity in a unpurified protein preparation immunodepleted of CFTR. ATP channel Po was increased by a pressure gradient, while GdCl3 decreased Po to virtually 0.00 (n = 6; see text for Po data).

We next asked the question: what if CFTR is removed from this material? Are CFTR Cl- channels and ATP channels lost or can this activity be dissociated? To answer these questions, CFTR was immunodepleted out of this material, and this preparation was fused with planar lipid bilayers. Importantly, an ATP conductance was still observed, even in the nominal absence of CFTR protein (Fig. 5B). In these experiments, a pressure gradient applied to the membrane increased the open probability (Po) of the ATP channel from 0.50 ± 0.10 to 0.80 ± 0.10, while GdCl3, a mechanosensitive ion channel blocker, decreased markedly the Po of ATP channels to 0.13 ± 0.05 (Fig. 5B; n = 6). DPC and DIDS, broad specificity Cl- channel blockers, also inhibit this ATP conductance (data not shown). Taken together, the simplest interpretation of these data is that an anion channel distinct from CFTR plays a primary role in conferring the ATP conductance measured in this assay. However, the ATP conductance appears to be closely associated with CFTR. Because this channel is inhibited by gadolinium chloride and DPC and activated by a pressure gradient, this ATP-permeable channel may belong to the family of mechanosensitive anion channels. Although these data argue that CFTR itself is not likely to conduct ATP, the possibility cannot be ruled out that a regulatory cofactor required to induce CFTR to conduct ATP may be purified away from CFTR in these experiments.

CFTR Expression, ATP Transport, Extracellular ATP Signaling, and Cell Volume Regulation Are Linked-- To provide a causal link between each of the entities described above, we tested the possibility that a mechanosensitive anion channel may be involved in conductive ATP transport out of cells and autocrine control of RVD. Focusing again on WT-CFTR-expressing fibroblasts, Fig. 6 shows the effect of ion channel-blocking drugs on basal and hypotonicity-induced ATP release and on RVD dynamics. DIDS, a broad specificity Cl- channel and transporter blocking drug, was used in lieu of DPC, because DPC has inhibitory effects on the luciferase detection reagent while DIDS and GdCl3 do not (see Fig. 6 legend for data). The presence of DIDS blocked fully basal and hypotonicity-induced ATP release (Fig. 6A, left panel) and inhibited RVD markedly (Fig. 6A, right panel). To confirm that DIDS was inhibiting RVD through effects on ATP release, ATPgamma S was added in the presence of DIDS. ATPgamma S rescued the effects of DIDS fully (Fig. 6A, right panel), consistent with an effect of DIDS as an inhibitor of autocrine ATP control of cell volume regulation. Similar experiments were performed with the mechanosensitive ion channel blocker, GdCl3. GdCl3 inhibited basal and hypotonicity-induced ATP release markedly (Fig. 6B, left panel). GdCl3 also blocked RVD and caused cells to swell markedly (Fig. 6B, right panel). Again, exposure to ATPgamma S partially reversed the effect on cell volume (Fig. 6B, right panel).



View larger version (25K):
[in this window]
[in a new window]
 
Fig. 6.   Ion channel blocking drugs inhibit hypotonicity-induced ATP release and RVD. WT-CFTR-expressing fibroblasts were assessed with both assays. A: right panel, representative ATP release assay under isotonic and hypotonic conditions; DIDS inhibited both basal and hypotonicity-induced ATP release fully (representative of six independent experiments). A: right panel, RVD measurements in the absence of either drug, in the presence of DIDS, and in the presence of DIDS plus ATPgamma S (n = 3 each). DIDS blocked RVD; ATPgamma S rescued DIDS inhibition. B: left panel, representative ATP release assay under isotonic and hypotonic conditions; GdCl3 inhibited both basal and hypotonicity-induced ATP release markedly (representative of nine independent experiments). B: right panel, RVD measurements in the absence of either drug, in the presence of GdCl3, and in the presence of GdCl3 plus ATPgamma S (n = 3 for each fibroblast clone). GdCl3 blocked RVD and caused cells to swell to a greater degree than DIDS; ATPgamma S blocked partially GdCl3-induced swelling, but failed to fully rescue RVD (n = 3 each). With respect to effects on luciferase activity, bioluminescence detection of known amounts of ATP in the presence and absence of GdCl3 and DIDS (200 µM) was assessed: 10-7 M ATP: control, 189 ± 4 ALU; DIDS, 178 ± 6 ALU; GdCl3, 190 ± 5 ALU; 10-6 M ATP: control, 1378 ± 111 ALU; DIDS, 1466 ± 55; GdCl3, 1257 ± 85 (n = 3 each). In contrast, DPC (200 µM) inhibited luciferase activity 100-fold (data not shown).

WT-CFTR and Extracellular ATP Signaling Are Required for Volume-sensitive Cl- Permeability-- RVD depends upon activation of a volume-sensitive anion conductance in most cells. To measure hypotonicity-induced Cl- channel activity in multiple cells within a culture, SPQ halide fluorophore imaging assays were performed on cells that lacked or expressed WT or mutant CFTR. COS-7 cells infected with T7 vaccinia virus controls or virus bearing WT-CFTR or Delta F508-CFTR were compared for either forskolin- or hypotonicity-induced SPQ fluorescence. While T7 controls failed to respond significantly to forskolin (permeability coefficient or pI = 0.29), a small increase in SPQ fluorescence was observed with a 25% hypotonic challenge (pI = 0.71; Fig. 7C). Overexpression of WT-CFTR-expressing cultures responded robustly and reversibly to both stimuli (Fig. 7A), with permeability coefficients that were 10-fold greater for forskolin (pI = 3.86) and 3.5-fold greater for hypotonicity (pI = 2.37) versus T7 controls. Delta F508-CFTR-expressing cultures had an intermediate response to both stimuli (forskolin pI = 0.47 and hypotonicity pI = 1.33; Fig. 7B), consistent with the modest effects of Delta F508-CFTR on ATP release. Because overexpression of CFTR may overestimate CFTR function, CFT-1 CF epithelial cells homozygous for the Delta F508-CFTR mutation were transiently transfected with WT-CFTR plasmid constructs (Fig. 7D). Although levels of expression are lower than in vaccinia-driven systems, WT-CFTR also potentiated hypotonicity-induced Cl- efflux (pI = 18.77 versus pI of "mock" control = 7.03; Fig. 7D). In 9HTEo- non-CF airway epithelial cells expressing WT-CFTR, hypotonicity-induced Cl- efflux was assessed in the absence and presence of hexokinase or apyrase, two different ATP scavengers. As with RVD assays shown above, the ATP scavenger blunted hypotonicity-induced Cl- efflux (hypotonicity pI = 5.29; hypotonicity + hexokinase pI = 0.59; hypotonicity + apyrase pI = -0.03; Fig. 7E), suggesting that extracellular autocrine ATP signaling is required for triggering Cl- efflux during RVD. Hypotonicity fails to increase cyclic AMP levels, suggesting that stimulation of CFTR Cl- channel activity is not contributing to hypotonicity-induced Cl- efflux (Fig. 7F). Taken together, these data indicate that both CFTR and extracellular ATP signaling are required for volume-sensitive Cl- efflux during RVD.



View larger version (51K):
[in this window]
[in a new window]
 
Fig. 7.   Hypotonicity-induced Cl- permeability is augmented by WT-CFTR and attenuated by ATP scavengers. A-C, comparison of forskolin and 25% hypotonicity-induced Cl- permeability (measured by fluorescence of the halide fluorophore, SPQ) in COS-7 cells infected with T7 control virus (C) or vaccinia virus bearing WT-CFTR (A) or Delta F508-CFTR (B) (number of cells screened shown in parentheses; result was repeated in three independent infections; pI = permeability coefficient following stimulation with forskolin or hypotonicity). D, CFT-1 CF epithelial cells transiently transfected with WT-CFTR when compared with mock-transfected cells (number of cells screened was 25; result representative of three independent transfections). E, comparison in 9HTEo- non-CF airway epithelial cells of hypotonicity-induced Cl- permeability in the absence and presence of two different ATP scavengers, apyrase and hexokinase (2 units/ml each) (number of cells screened was 25; result representative of three independent sets of experiments). HYPO, hypotonic. F, cellular cyclic AMP levels in response to forskolin (FORSK) or 25% hypotonic (HYPO) challenge and companion controls using a bioassay (n = 3-6; forskolin-induced cAMP levels were p < 0.05 greater than all other samples by ANOVA). PAP, papaverine.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

CFTR-dependent ATP Release and Signaling-- Potential interactions between ABC transporters and ATP signaling pathways have been difficult to define. The primary observations of these studies are that CFTR expression 1) enhances cell volume recovery from swelling or RVD, 2) stimulates both constitutive and volume-sensitive ATP release, and 3) facilitates autocrine control of cell volume regulation via purinergic receptors. While the mechanism of ATP release is not fully defined, these effects appear to be due to CFTR-dependent modulation of a separate ATP channel. These results are in agreement with volume-sensitive ATP release and ABC transporter potentiation of that release in hepatocytes and biliary epithelial cells (5,52). These studies also synergize with evidence for CFTR-dependent ATP release in red blood cells (53) and defective cell volume regulation in CF (-/-) intestinal crypts (54). These results also correlate with work implicating the closest relative of CFTR, the ABC transporter mdr-1 or P-glycoprotein, initially as a volume-activated Cl- channel and later as a regulator of volume-activated Cl- channels (31-33). Indeed, mdr-1 was also shown recently to accelerate RVD in heterologous cells (34). Thus, CFTR may function as a versatile and sensitive transducer that modulated volume-sensitive ATP release and membrane ion permeability.

Based on these observations, our working hypothesis is that cell volume is sensed and transduced in an ABC transporter-dependent manner, leading to potentiation of ATP release through stimulation of a separate, yet tightly associated, ATP channel. In lipid bilayers, this ATP release pathway is stimulated by a transmembrane pressure gradient and is inhibited by the mechanosensitive ion channel blockers, the lanthanides (GdCl3 and LaCl3), and the broad specificity Cl- channel blockers, DIDS and DPC (Fig. 8). This working model is bolstered by the data that DIDS and GdCl3 do not inhibit CFTR Cl- channel activity. The finding that cyclic AMP potentiates volume-sensitive ATP release only in wild-type CFTR-expressing cells underscores a key regulatory role for CFTR in this process. Because the sensitivity as well as the magnitude of extracellular ATP release is lost in CF epithelia or in heterologous cells that lack wild-type CFTR, it is attractive to speculate that the sensor for hypotonicity may be related to CFTR itself. The possibility, that CFTR as well as other ABC transporters may be "sensors" or receptors, has been suggested in a previous report (23).



View larger version (37K):
[in this window]
[in a new window]
 
Fig. 8.   Working model of CFTR and purinergic signaling in normal versus CF epithelia: loss of CFTR and purinergic signaling leads to defects in cell volume regulation and may lead to abnormal airway surface liquid composition and/or volume. Shown is a working model illustrating non-CF epithelial cell's ability to sense hypotonicity (as reduced or diluted external Cl- ions) in a CFTR-dependent manner, intact purinergic signaling from a non-CF cells that is antagonized by ATP scavengers and ATP release channel inhibitors, and ATP- and hypotonicity-induced Cl- efflux and RVD. In a CF cell, all is attenuated due to a lack of CFTR in the apical membrane, defects in epithelial cell volume regulation, and dysregulation of other anion and cation conductances.

ATP Release Channel Can Be Dissociated from CFTR-- The specific cellular mechanisms whereby CFTR facilitates the release of ATP are not known and are limited by the lack of a molecular candidate other than CFTR (14, 19-30). Observations herein are consistent with the view that CFTR itself does not conduct ATP but, instead, is associated closely with a separate ATP-permeant channel that is expressed in both epithelial and heterologous cells. First, an ATP channel conductance was not reliably detected in a highly purified preparation of CFTR in lipid bilayers, consistent with other published work (28, 30). Second, in less purified systems containing many proteins, both Cl- and ATP channels are observed. Third, ATP channels are still detectable after rigorous immunodepletion of CFTR. The fact that ATP channels are active independently of CFTR is intriguing and suggests that, in the bilayer, the cofactor regulatory machinery is no longer present. These findings are consistent with other studies that demonstrate that ATP release from intact cells is diminished but still detectable in the absence of CFTR. It is important to emphasize, however, that CFTR, as a member of the ABC transporter family, may transport ATP itself, albeit at rates that are nonconductive and more consistent with a transporter. Moreover, it is also possible that CFTR may transport ATP at conductive rates, in that purification of CFTR may have eliminated a regulatory protein that is essential for helping CFTR conduct ATP. These uncertainties underscore the need for identification of new molecular candidates for the ATP release pathway.

In this light, several anion channels beyond CFTR are candidates for ATP release channels. For example, because DIDS inhibits ORCCs, because ORCC Cl- channels are present in the less purified protein material derived from bovine tracheal epithelial membrane vesicles, and because ORCCs are stimulated by membrane stretch (55), it is possible that ORCCs may function as a conduction pathway for ATP. Voltage-sensitive organic anion channels are blocked in a voltage-dependent manner by 10 mM ATP as an open channel blocker (56); as such, voltage-sensitive organic anion channels may also be permeable to ATP. Thinnes and colleagues (57) have identified plasma membrane-expressed forms of the voltage-dependent anion channel (PL-VDAC) or "porin," which, in inner mitochondrial membrane, functions to conduct newly synthesized ATP in and out of the mitochondrion. Plasmalemmal forms of VDAC may also conduct ATP (57). These or other ATP-permeable channels may also be present in vesicles (as borne out by the bilayer studies) and may be inserted into the plasma membrane as ATP-filled vesicles fuse to release ATP by an exocytic mechanism (9).

CFTR as a Cell Volume Regulator-- These considerations suggest a working model for ATP release and signaling that places CFTR in a different context (Fig. 8). In non-CF cells, this signaling system would be active under basal conditions, and volume-sensitive ATP release would be augmented by hypotonicity and would culminate in normal RVD in a manner governed by CFTR at the apical plasma membrane (Fig. 8). However, in CF cells with the Delta F508 mutation, the lack of functional CFTR leads to impaired ATP release and a depletion of this autocrine signaling system. The result is that cell volume regulation would be desensitized or down-regulated under both basal and hypotonic conditions (Fig. 8). Theoretically, in the CF epithelium, this could lead to an impaired ability to maintain normal cell volume under basal conditions and a decreased ability to RVD under hypotonic conditions. Indeed, abnormalities in ionic and osmotic strength and/or volume of CF airway surface liquid have been measured in multiple studies (35-38). The fact that airway surface liquid appears regulated in its depth and in its composition implies a regulatory role of the airway surface epithelium itself and an involvement of cell volume regulatory processes. Thus, dysfunction of RVD mechanisms, cell volume regulation, or both due to defective CFTR and a lack of extracellular autocrine ATP signaling may contribute to the pathogenesis of CF lung dysfunction.


    ACKNOWLEDGEMENTS

All authors contributed much to this work in a team effort! We thank Dieter Gruenert for the non-CF and CF airway epithelial cell models; Monique Mansoura and Melissa Ashlock at the NHGRI for the gift of the CFT-1 cells as well as their YAC clones; and Pary Weber, Michael Welsh, and the Howard Hughes Medical Institute for the generous gift of the 3T3 fibroblasts expressing wild-type and Delta F508 CFTR.


    FOOTNOTES

* This work was supported by a CF New Investigator Grant from the Cystic Fibrosis Foundation (CFF) (to E. M. S.), by National Institutes of Health Grant R01 DK/HL 54367 (to E. M. S.), by a CF New Investigator Grant and Research Grant from the CFF (to L. M. S.), by an National Institutes of Health Grant DK-48764 (to D. J. B.), by a CFF Fellowship F981 (to B. J.), and by a Leroy Matthews award from the CFF (to J. P. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§§ To whom correspondence should be addressed: Assistant Professor of Physiology and Biophysics, Assistant Professor of Cell Biology, and Research Scientist in the Gregory Fleming James CF Research Center, University of Alabama at Birmingham, BHSB 740, 1918 University Blvd., Birmingham, AL 35294-0005. Tel.: 205-934-6234; Fax: 205-934-1445; E-mail: eschwiebert@physiology.uab.edu.

Published, JBC Papers in Press, November 10, 2000, DOI 10.1074/jbc.M005893200


    ABBREVIATIONS

The abbreviations used are: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; ABC, ATP-binding cassette; SPQ, 6-methoxy-N-(3-sulfopropyl)quinolinium, inner salt; WT, wild-type; RVD, regulatory volume decrease; ATPgamma S, adenosine 5'-O-(thiotriphosphate); ALU, arbitrary light unit(s); DPC, diphenylamine carboxylic acid; DIDS, 4,4'-diisothiocyanatostilbene-2,2'disulfonic acid; ORCC, outwardly rectifying Cl- channel; ANOVA, analysis of variance.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES


1. Barnard, E. A., Burnstock, G., and Webb, T. E. (1994) Trends Pharmacol. Sci. 15, 67-70[CrossRef][Medline] [Order article via Infotrieve]
2. Buell, G., Collo, G., and Rassendren, F. (1996) Eur. J. Neurosci. 8, 2221-2228[Medline] [Order article via Infotrieve]
3. Valera, S., Hussy, N., Evans, R. J., Adami, N., North, R. A., Surprenant, A., and Buell, G. (1994) Nature 371, 516-519[CrossRef][Medline] [Order article via Infotrieve]
4. Gordon, J. L. (1986) Biochem. J. 233, 309-319[Medline] [Order article via Infotrieve]
5. Wang, Y., Roman, R., Lidofsky, S. D., and Fitz, J. G. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 12020-12025[Abstract/Free Full Text]
6. Roman, R. M., Wang, Y., and Fitz, J. G. (1996) Am. J. Physiol. 271, G239-G248[Abstract/Free Full Text]
7. Urbach, V., and Harvey, B. J. (1999) J. Membr. Biol. 171, 255-265[CrossRef][Medline] [Order article via Infotrieve]
8. Frame, M. K., and de Feijter, A. W. (1997) Exp. Cell Res. 230, 197-207[CrossRef][Medline] [Order article via Infotrieve]
9. Hollins, B., and Ikeda, S. R. (1997) J. Neurophysiol. 78, 3069-3076[Abstract/Free Full Text]
10. Musante, L., Zegarra-Moran, O., Montaldo, P. G., Ponzoni, M., and Galietta, L. J. V. (1999) J. Biol. Chem. 274, 11701-11707[Abstract/Free Full Text]
11. Knowles, M. R., Clarke, L. L., and Boucher, R. C. (1991) N. Engl. J. Med. 325, 533-538[Abstract]
12. Knowles, M. R., Clarke, L. L., and Boucher, R. C. (1992) Chest 101, 60-63
13. Stutts, M. J., Fitz, J. G., Paradiso, A. M., and Boucher, R. C. (1994) Am. J. Physiol. 267, C1442-C1451[Abstract/Free Full Text]
14. Schwiebert, E. M., Egan, M. E., Hwang, T.-H., Fulmer, S. B., Allen, S. S., Cutting, G. R., and Guggino, W. B. (1995) Cell 81, 1063-1073[Medline] [Order article via Infotrieve]
15. Hwang, T.-H., Schwiebert, E. M., and Guggino, W. B. (1996) Am. J. Physiol. 270, C1611-C1623[Abstract/Free Full Text]
16. Inoue, C. N., Woo, J.-S., Schwiebert, E. M., Morita, T., Hanaoka, K., Guggino, S. E., and Guggino, W. B. (1997) Am. J. Physiol. 272, C1862-C1870[Abstract/Free Full Text]
17. Cantiello, H. F., Prat, A. G., Reisin, I. L., Ercole, L. B., Abraham, E. H., Amara, J. F., Gregory, R. J., and Ausiello, D. A. (1994) J. Biol. Chem. 269, 11224-11232[Abstract/Free Full Text]
18. Lazarowski, E. R., Mason, S. J., Clarke, L. L., Harden, T. K., and Boucher, R. C. (1992) Br. J. Pharmacol. 106, 774-782[Abstract]
19. Reisin, I. L., Prat, A. G., Abraham, E. H., Amara, J. F., Gregory, R. J., Ausiello, D. A., and Cantiello, H. F. (1994) J. Biol. Chem. 269, 20584-20591[Abstract/Free Full Text]
20. Abraham, E. H., Prat, A. G., Gerweck, L., Seneveratne, T., Arceci, R. J., Kramer, R., Guidotti, G., and Cantiello, H. F. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 312-316[Abstract]
21. Abraham, E. H., Okunieff, P., Scala, S., Vos, P., Oosterveld, M. J. S., Chen, A. Y., and Shrivastav, B. (1997) Science 275, 1324-1325[Free Full Text] (Technical Comment)
22. Pasyk, E. A., and Foskett, J. K. (1997) J. Biol. Chem. 272, 7746-7751[Abstract/Free Full Text]
23. Jiang, Q., Mak, D., Devidas, S., Schwiebert, E. M., Bragin, A., Zhang, Y., Skach, W. R., Guggino, W. B., Foskett, J. K., and Engelhardt, J. F. (1996) J. Cell Biol. 143, 645-657[Abstract/Free Full Text]
24. Sugita, M., Yue, Y., and Foskett, J. K. (1998) EMBO J. 17, 898-908[Abstract/Free Full Text]
25. Grygorczyk, R., and Hanrahan, J. W. (1997) Am. J. Physiol. 272, C1058-C1066[Abstract/Free Full Text]
26. Reddy, M. M., Quinton, P. M., Haws, C., Wine, J. J., Grygorczyk, R., Tabcharani, J. A., Hanrahan, J. W., Gunderson, K. L., and Kopito, R. R. (1997) Science 275, 1325[CrossRef] (Technical Comment)
27. Grygorczyk, R., and Hanrahan, J. W. (1997) Science 275, 1325-1326[CrossRef] (Technical Comment)
28. Reddy, M. M., Quinton, P. M., Haws, C., Wine, J. J., Grygorczyk, R., Tabcharani, J. A., Hanrahan, J. W., Gunderson, K. L., and Kopito, R. R. (1996) Science 271, 1876-1879[Abstract]
29. Watt, W. C., Lazarowski, E. R., and Boucher, R. C. (1998) J. Biol. Chem. 273, 14053-14058[Abstract/Free Full Text]
30. Li, C., Ramjeesingh, M., and Bear, C. E. (1996) J. Biol. Chem. 271, 11623-11626[Abstract/Free Full Text]
31. Higgins, C. F. (1995) Cell 82, 693-696[Medline] [Order article via Infotrieve]
32. Valverde, M. A., Diaz, M., Sepulveda, F. V., Gill, D. R., Hyde, S. C., and Higgins, C. F. (1992) Nature 355, 830-833[CrossRef][Medline] [Order article via Infotrieve]
33. Gill, D. R., Hyde, S. C., Higgins, C. F., Valverde, M. A., Mintenig, G. M., and Sepulveda, F. V. (1992) Cell 71, 23-32[Medline] [Order article via Infotrieve]
34. Valverde, M. A., Bond, T. D., Hardy, S. P., Taylor, J. C., Higgins, C. F., Altamirano, J., and Alvarez-Leefmans, F. J. (1996) EMBO J. 15, 4460-4468[Abstract]
35. Smith, J. J., Travis, S. M., Greenberg, E. P., and Welsh, M. J. (1996) Cell 85, 229-236[Medline] [Order article via Infotrieve]
36. Matsui, H., Grubb, B. R., Tarran, R., Randell, S. H., Gatzy, J. T., Davis, C. W., and Boucher, R. C. (1998) Cell 95, 1005-1015[Medline] [Order article via Infotrieve]
37. Zhang, Y., and Engelhardt, J. F. (1999) Am. J. Physiol. 276, C469-C476[Abstract/Free Full Text]
38. Guggino, W. B. (1999) Cell 96, 607-610[Medline] [Order article via Infotrieve]
39. Kunzelmann, K., Schwiebert, E. M., Zeitlin, P. L., Kuo, W.-L., Stanton, B. A., and Gruenert, D. C. (1993) Am. J. Respir. Cell Mol. Biol. 8, 522-529[Medline] [Order article via Infotrieve]
40. Cozens, A. L., Yezzi, M. J., Chin, L., Simon, E. M., Friend, D. S., and Gruenert, D. C. (1991) Adv. Exp. Med. Biol. 290, 187-196[Medline] [Order article via Infotrieve]
41. Cozens, A. L., Yezzi, M. J., Yamaya, M., Steiger, D., Wagner, J. A., Garber, S. S., Chin, L., Simon, E. M., Cutting, G. R., Gardner, P., et al.. (1992) In Vitro Cell. Dev. Biol. 28A, 735-744
42. Taylor, A. L., Kudlow, B. A., Marrs, K. L., Gruenert, D. C., Guggino, W. B., and Schwiebert, E M. (1998) Am. J. Physiol. 275, C1391-C1406[Medline] [Order article via Infotrieve]
43. Drumm, M. L., Pope, H. A., Cliff, W. H., Rommens, J. M., Marvin, S. A., Tsui, L.-C., Collins, F. S., Frizzell, R. A., and Wilson, J. M. (1990) Cell 62, 1227-1233[Medline] [Order article via Infotrieve]
44. Anderson, M. P., Rich, D. P., Gregory, R. J., Smith, A. E., and Welsh, M. J. (1991) Science 251, 679-682[Medline] [Order article via Infotrieve]
45. Schwiebert, L. M., Estell, K., and Propst, S. M. (1999) Am. J. Physiol. 276, C700-C710[Abstract/Free Full Text]
46. Schwiebert, E. M., Morales, M. M., Devidas, S., Egan, M. E., and Guggino, W. B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2674-2679[Abstract/Free Full Text]
47. Cheng, S. H., Gregory, R., Marshall, J., Paul, S., Souza, D. W., White, G. A., O'Riordan, C. R., and Smith, A. E. (1990) Cell 63, 827-834[Medline] [Order article via Infotrieve]
48. Clancy, J. P., Ruiz, F. E., and Sorscher, E. J. (1999) Am. J. Physiol. 276, C361-C369[Abstract/Free Full Text]
49. Jovov, B., Ismailov, I. I., and Benos, D. J. (1995) J. Biol. Chem. 270, 1521-1528[Abstract/Free Full Text]
50. Jovov, B., Ismailov, I. I., Berdiev, B. K., Fuller, C. M., Sorscher, E. J., Dedman, J. R., Kaetzel, M. A., and Benos, D. J. (1995) J. Biol. Chem. 270, 29194-29200[Abstract/Free Full Text]
51. Welsh, M. J., and Smith, A. E. (1993) Cell 73, 1251-1254[Medline] [Order article via Infotrieve]
52. Roman, R. M., Wang, Y., Lidofsky, S. D., Feranchak, A. P., Lomri, N., Scharschmidt, B. F., and Fitz, J. G. (1997) J. Biol. Chem. 272, 21970-21976[Abstract/Free Full Text]
53. Sprague, R. S., Ellsworth, M. L., Stephenson, A. H., Kleinhenz, M. E., and Lonigro, A. J. (1998) Am. J. Physiol. 275, H1726-H1732[Abstract/Free Full Text]
54. Valverde, M. A., O'Brien, J. A., Sepulveda, F. V., Ratcliff, R. A., Evans, M. J., and Colledge, W. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9038-9041[Abstract]
55. Solc, C. K., and Wine, J. J. (1991) Am. J. Physiol. 261, C658-C674[Abstract/Free Full Text]
56. Jackson, P. S., and Strange, K. (1995) J. Gen. Physiol. 105, 661-677[Abstract]
57. Reymann, S., Florke, H., Heiden, M., Jakob, C., Stadtmuller, U., Steinacker, P., Lalk, V. E., Pardowitz, I., and Thinnes, F. P. (1995) Biochem. Mol. Med. 54, 75-87[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.